Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 -March 27, 2024 at 12:45 pm EDT

2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation activity to...

Related Keywords

France ,Ottawa ,Ontario ,Canada ,John Felitti ,Frazer Hall Sylvie Berrebi ,Lucie Larguier ,Christelle Schwoerer ,Maud Brandely Talbot ,Christophe Ancel ,Transgene Euronext ,Johnc Bell ,Carol Stuckley ,Pedro Romero ,James Wentworth ,Alessandro Riva ,Canadian Oncolytic Virus Consortium ,Twitter ,Linkedin ,Merck Co ,Transgene Management Committee ,Astrazeneca ,University Of Lausanne ,Euronext Paris ,European Journal ,Phasei Delivir ,Management Committee ,Chief Executive Officer ,Chief Scientific Officer ,Chief Pharmaceutical Operations Officer ,Qualified Pharmacist ,Chief Medical ,Regulatory Officer ,Chief Financial Officer ,Chief Business Officer ,General Counsel ,Corporate Secretary ,Chief Human Resources Officer ,Combined General Meeting ,Senior Scientist ,Cancer Therapeutics Program ,Ottawa Hospital Research Institute ,Tasly Biopharmaceuticals ,Artificial Intelligence ,Risk Factors ,Universal Registration Document ,Management Discussion ,Markets ,